85% lower disease progression with early use of HCQ. Retrospective 616 patients in China showing adjusted progression HR 0.15, p
Su et al., 12/23/2020, retrospective, China, Asia, peer-reviewed, 9 authors, dosage 400mg days 1-10, 400mg daily for 10-14 days.
risk of disease progression, 84.9% lower, RR 0.15, p = 0.006, treatment 261, control 355, adjusted per study, binary logistic regression.
improvement time, 24.0% lower, relative time 0.76, p = 0.02, treatment 261, control 355, adjusted per study, Cox proportional hazards regression.
Effect extraction follows pre-specified rules prioritizing more serious
outcomes. For an individual study the most serious outcome may have a smaller
number of events and lower statistical signficance, however this provides the
strongest evidence for the most serious outcomes when combining the results of